BioMag Receives Second Patent on Its High Throughput Screening - Magnetic Testing Platform
News May 11, 2006
BioMag Corp., through its wholly owned subsidiary Biospectrum Technologies Inc., has announced that it has received its second patent from the U.S. Patent office on its High Throughput Screening - Magnetic Testing Platform (HTS-MTP) that is designed to produce both qualitative (yes/no) and quantitative (viral load) results from a single test.
Clayton Hardman, president and CEO of BioMag Corp., stated, "In addition to the HTS-MTP patent that was received from the U.S. Patent office in July of 2003, we have just received our second patent, further establishing our technology and enabling a broad spectrum of applications in which our product applies, in both medical testing and diagnostics."
"It is safe to say that our product is one of a kind in which can potentially revolutionize the diagnostic industry."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018